Other Event

Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event


Ignite Creation Date: 2025-12-24 @ 10:04 PM
Ignite Modification Date: 2025-12-25 @ 7:40 PM
NCT ID: NCT04191135
Term: White blood cell count decreased
Organ System: Investigations
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA 25.1
Notes: None
Study: NCT04191135
Study Brief: Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG002 78 28 133 View
EG000 149 71 460 View
EG001 29 14 135 View